



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re: Nyce J. W.

Serial. No.: 09\543,679 : Group Art Unit: 1615

Filing Date: April 4, 2000 : Examiner: Not Yet Assigned

For: Low Adenosine Anti-Sense Oligonucleotide, Compositions, Kit & Method for Treatment of Airway Disorders Associated with Bronchoconstriction, Lung Inflammation, Allergy(ies) & Surfactant Depletion

STATEMENT UNDER 37 CFR 1.825(a) AND (b)

Assistant Commissioner for Patents
Washington D C 20231

Sir\Madam:

I, Viviana Amzel, hereby state that (1) the amendments, made in accordance with 37 CFR 1.825(a) and included in the substitute copy of the Sequence Listing filed herewith, are supported in the application as filed; (2) the enclosed substitute Sequence Listing includes no new matter and the sequences therein are, to the best of applicant's knowledge, substantially the same, and (3) the substitute copy of the computer readable form, submitted in accordance with 37 CFR 1.825(b), is the same as the amended Sequence Listing.

Thus, applicant has fully met the requirements of 37 CFR 1.821 through 1.825 for patent applications containing nucleotide sequence and/or amino acid sequence disclosures.

Respectfully submitted,
EPIGENESIS PHARMACEUTICALS, INC

3/21/01

Date

Viviana Amzel, Ph. D.

Reg. No. 30,930

Attorney for the Applicant

7 Clarke Drive
Cranbury, NJ 08512
609-409-3035 Legal Dept Ph.
413-254-9245 Legal Dept Fax
Vamzel@epigene.com
S:\Legal\00671b\Dec - Seq Lst - 2001-03-21.doc

I hereby certify that this correspondence is being deposited with the United States Postal Service, First Class Mail, under 37 CFR 1.10 and addressed to Box Sequence, Assistant Commissioner for Patents, on March 21, 2001 by Dee Dee Sutherland

Dee Dee Sutherland
SIGNATURE